Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Clinical and Translational Medicine(2024)10.1002/ctm2.70057Source: DataRank Database

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas is a research paper published in Clinical and Translational Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.28)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Abhilash Venugopalan ORCID,Jingli Zhang ORCID,Nishanth Ulhas Nair ORCID,Manjistha Sengupta ORCID,Manakamana Khanal ORCID

Live enrichment

PubMed:39548594 PMC:PMC11567854 OpenAlex:https://openalex.org/W4404446267

Center for Cancer Research

Grant: ZIA‐BC‐010816

CCR NIH HHS

Grant: ZIA-BC-010816

National Institutes of Health

Grant: 1ZIABC010816-10

Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies

Intramural Research Program of the NIH

NCI NIH HHS

Intramural Research Program of the NIH

NCI NIH HHS

FWCI

1.28

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctm2.70057

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctm2.70057

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.70057

journalhttps://doi.org/10.1002/ctm2.70057

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39548594

Fields of Study

CAR-T cell therapy researchSafe Handling of Antineoplastic Drugs0301 basic medicine0303 health sciences03 medical and health sciencesMesothelinHumansStomach NeoplasmsColorectal NeoplasmsMiceAnimalsReceptors, Chimeric AntigenCell Line, TumorImmunotherapy, AdoptiveGPI-Linked Proteins

MeSH Terms

Receptors, Chimeric AntigenMesothelinAnimalsHumansStomach NeoplasmsColorectal NeoplasmsImmunotherapy, AdoptiveCell Line, TumorMiceGPI-Linked Proteins

Keywords

MesothelinCancer researchPembrolizumabColorectal cancerMedicineChimeric antigen receptorCancerCytotoxic T cellFlow cytometryAntigenCytokineImmunotherapyIn vitroBiologyImmunologyInternal medicineGastric cancerCar T CellAnti‐pd1Xenograft Cancer ModelMedicine (General)Receptors, Chimeric AntigenGPI-Linked ProteinsImmunotherapy, AdoptiveMiceR5-920Stomach NeoplasmsCell Line, TumorHumansAnimalsColorectal NeoplasmsResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being